UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma

International journal of molecular sciences, 2023-12, Vol.25 (1), p.549

2023

Volltextzugriff (PDF)

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study

Annals of hematology, 2020-06, Vol.99 (6), p.1273-1281

2020

Volltextzugriff (PDF)

The enigma of LAG3 receptor in hematological malignancies

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3019-3020

2022

Volltextzugriff (PDF)

Understanding high-risk smoldering multiple myeloma

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-12

2023

Volltextzugriff (PDF)

Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma

Hematological oncology, 2018-02, Vol.36 (1), p.349-354

2018

Volltextzugriff (PDF)

Bad players in AL amyloidosis in the current era of treatment

Expert review of hematology, 2023, Vol.16 (1), p.33-49

2023

Volltextzugriff (PDF)

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

The Lancet (British edition), 2023-01, Vol.401 (10373), p.269-280

2023

Volltextzugriff (PDF)

The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7112-7113

2022

Volltextzugriff (PDF)

The Involvement of LAG-3[sup.positive] Plasma Cells in the Development of Multiple Myeloma

International journal of molecular sciences, 2023-12, Vol.25 (1)

2023

Volltextzugriff (PDF)

Shiga-like Toxin Producing E. coli Identified in Patients with Multiple Myeloma (MM) Hospitalized Due to Acute Onset Diarrhea; First Report on the Clinical Use of the Biofire Film Array Gastrointestinal Panel

Blood, 2018-11, Vol.132 (Supplement 1), p.4959-4959

2018

Volltextzugriff (PDF)

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Blood, 2019-11, Vol.134 (Supplement_1), p.3902-3902

2019

Volltextzugriff (PDF)

Shiga-Like Toxin-Producing Escherichia coli Inducing Diarrhea in Patients with Multiple Myeloma Diagnosed by BioFire PCR-Film Array

Acta haematologica, 2019-09, Vol.142 (3), p.187-189

2019

Volltextzugriff (PDF)

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1972-1972

2018

Volltextzugriff (PDF)

Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen

Hematological oncology, 2021-02, Vol.39 (1), p.129-133

2021

Volltextzugriff (PDF)

The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2017-12, Vol.17 (12), p.863-869

2017

Volltextzugriff (PDF)

Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?

Anticancer research, 2016-06, Vol.36 (6), p.2889-2892

2016

Volltextzugriff (PDF)

The Involvement of LAG-3 positive Plasma Cells in the Development of Multiple Myeloma

International journal of molecular sciences, 2023-12, Vol.25 (1)

2023

Volltextzugriff (PDF)

Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Clinical lymphoma, myeloma and leukemia, 2020-11, Vol.20 (11), p.e850-e857

2020

Volltextzugriff (PDF)

Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e296-e296

2019

Volltextzugriff (PDF)

Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

The Lancet. Haematology, 2023-12, Vol.10 (12), p.e955-e965

2023

Volltextzugriff (PDF)

Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?

Leukemia & lymphoma, 2018-05, Vol.59 (5), p.1163-1171

2018

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Hematology
(12)
Humans
(11)
Oncology
(9)
Multiple Myeloma
(6)
Female
(5)
Aged
(4)
Middle Aged
(4)
Clinical Trials
(3)
Cll
(3)
Male
(3)
Plasma Cells
(3)
Anemia
(2)
Antibodies
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Bone Marrow
(2)
Chemical Compounds
(2)
Chronic Lymphocytic Leukemia
(2)
Cluster Of Differentiation-8
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study

The enigma of LAG3 receptor in hematological malignancies

Understanding high-risk smoldering multiple myeloma

Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma

Bad players in AL amyloidosis in the current era of treatment

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma

The Involvement of LAG-3[sup.positive] Plasma Cells in the Development of Multiple Myeloma

Shiga-like Toxin Producing E. coli Identified in Patients with Multiple Myeloma (MM) Hospitalized Due to Acute Onset Diarrhea; First Report on the Clinical Use of the Biofire Film Array Gastrointestinal Panel

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Shiga-Like Toxin-Producing Escherichia coli Inducing Diarrhea in Patients with Multiple Myeloma Diagnosed by BioFire PCR-Film Array

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen

The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia

Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?

The Involvement of LAG-3 positive Plasma Cells in the Development of Multiple Myeloma

Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study

Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study

Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?

Suchergebnisse filtern